This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2012 Jul;98(14):1037-9.

doi: 10.1136/heartjnl-2012-301649.

Understanding the cost-effectiveness of bivalirudin

Amit P Amin, Elizabeth A Magnuson

PMID: 22739634
DOI: 10.1136/heartjnl-2012-301649

Editorial

Understanding the cost-effectiveness of bivalirudin

Amit P Amin et al. Heart. 2012 Jul.

. 2012 Jul;98(14):1037-9.

doi: 10.1136/heartjnl-2012-301649.

Authors

Amit P Amin, Elizabeth A Magnuson

PMID: 22739634
DOI: 10.1136/heartjnl-2012-301649

No abstract available

PubMed Disclaimer

Comment on

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction.
Schwenkglenks M, Toward TJ, Plent S, Szucs TD, Blackman DJ, Baumbach A. Schwenkglenks M, et al. Heart. 2012 Apr;98(7):544-51. doi: 10.1136/heartjnl-2011-301323. Epub 2012 Feb 7. Heart. 2012. PMID: 22313548 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information